[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
April 9, 2014

Codevelopment of Genome-Based Therapeutics and Companion DiagnosticsInsights From an Institute of Medicine Roundtable

Author Affiliations
  • 1Janssen Diagnostics Oncology Research and Development, Raritan, New Jersey
  • 2Aetna, Sugar Land, Texas
  • 3University of Vermont College of Medicine, Burlington
JAMA. 2014;311(14):1395-1396. doi:10.1001/jama.2014.1508

More than 100 therapeutics, mostly for oncology, have biomarker tests recommended in their US Food and Drug Administration (FDA) labels.1 Moreover, a strategy to codevelop and cosubmit to the FDA a diagnostic test (companion diagnostic [CoDx]) that specifically targets a drug to patients predicted to respond has had success recently with vemurafenib, targeting the BRAF V600 mutation in metastatic melanoma, and with crizotinib, targeting the EML4-ALK mutation in non–small cell lung cancer.2 Companion diagnostic tests define the subset of patients who are most likely to benefit from a therapy or who should not receive the therapy because of ineffectiveness or predicted adverse effects.3 Genome-based, targeted therapeutics and codeveloped CoDx tests are the foundation of personalized medicine and have potential for contributing to high-value health care.

First Page Preview View Large
First page PDF preview
First page PDF preview
×